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Background: The aim of this study was to identify more accurate variables to
improve prognostication of individual patients with colorectal liver metastases (CRLM).
Clinicopathological characteristics only partly explain the large range in survival rates.
Methods: MessengerRNA expression profiles of resected CRLM of two patient groups
were analysed by mRNA sequencing: poor survivors (death from recurrent disease
<30 months after surgery) and good survivors (no recurrent disease >60 months after
surgery). Tumour and adjacent liver parenchyma samples were analysed.
Results: MessengerRNA expression profiling of the tumour samples identified 77 genes
that were differentially expressed between the two survival groups at a False Discovery
Rate (FDR) <0.1. In the adjacent liver parenchyma samples only one gene, MTRNR2L1,
showed significantly higher expression in the good survivors. Pathway analysis showed
higher expression of immune-related and stroma-related genes in tumour samples from
good survivors. Expression data was then validated by immunohistochemistry in two
cohorts comprising a total of 125 patients. Immunohistochemical markers that showed to
be associated with good survival in the total cohort were: high K/L+ infiltration in tumour
stroma [p = 0.029; OR 2.500 (95% CI 1.100–5.682)] and high CD79A+ infiltration in
tumour stroma [p = 0.036; OR 2.428 (95%CI 1.062–5.552)].
Conclusions: A high stromal infiltration of CD79A+ B cells and K/L+ plasma cells might
be favourable prognostic biomarkers after surgery for CRLM.
Keywords: colorectal liver metastases, cancer, genetics, RNA sequencing, B cells, immunohistochemistry
INTRODUCTION
Colorectal cancer is the cancer with the third highest incidence in Europe, and it often
disseminates to the liver (1). Curative treatment by liver surgery is possible in about 10–20%
of patients with colorectal liver metastases (CRLM) (2, 3) and survival rates after surgery have
improved in the last decades, with reported 5-year survival rates ranging from 14 to 60% (4–6).
Clinicopathological characteristics can partly explain this large range, but they are inconsistent in
accurately determining the prognosis for the individual patient (7).
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Recent advances in technology have led to the notion that
molecular characteristics might outperform clinicopathological
scoring systems in predicting patient treatment and survival
(8). Four individual centres have published prognostic gene
signatures for colorectal liver metastases based on expression
microarrays, but no single gene was shared between the four
signatures (9–12).
As early as 1889, Paget suggested that it is not only the
metastatic tumour (the “seed”) but also the hosting organ or
tissue (the “soil”) that might be important for metastatic tumour
growth (13). Progression of remaining, clinically undetectable
metastatic tumour cells in the remnant liver after liver surgery
is dependent on both micrometastases and on a favourable
micro-environment (14–16). For example, it has been shown
that microRNA expression in adjacent liver parenchyma can be
associated with recurrent disease and patient survival (17).
In this study, we applied genome-wide mRNA expression
profiling by RNAseq in two patient groups selected on survival
after liver surgery for CRLM: poor survivors, those who died
from recurrences within 30 months after surgery, and good
survivors, those alive without recurrences 60 months or more
after surgery. Samples from both tumour tissue and adjacent
liver parenchyma were included. Immunohistochemistry was
performed in two cohorts to validate the RNAseq results on
protein level. The goal of this study was to identify molecular
markers for favourable patient survival.
MATERIALS AND METHODS
Patients and Samples
In this study we included patients from two tertiary referral
centres for liver surgery, the University Medical Centre
Groningen (UMCG, cohort 1) and the Erasmus Medical
Centre in Rotterdam (cohort 2). Patients were selected
from prospectively maintained databases. Inclusion criteria
were (1) R0 partial liver resection for CRLM, (2) no
neoadjuvant chemotherapy before liver surgery and no adjuvant
chemotherapy after liver surgery, (3) a Fong clinical risk score
(5) of 3 or lower, (4) no detectable extrahepatic disease at time
of surgery, (5) no other known malignant disease, and (6)
availability of fresh frozen (−80◦C) resected CRLM material. Of
note, (neo)adjuvant chemotherapy is not a standard treatment
in the Netherlands. None of the patients received perioperative
chemotherapy; neither neoadjuvant nor adjuvant after liver
surgery. Adjuvant chemotherapy after primary tumor resection
was allowed provided that it was not within 6 months before
liver surgery. Follow-up consisted of cross-sectional imaging and
measurement of carcinoembryonic antigen (CEA) serum levels
every 3–4 months during the first 2 years after liver resection
and at 6-month intervals afterwards up to 5 years. Samples of
two groups of patients with different survival rates were selected:
poor survivors, who died of recurrent disease within 30 months
after partial liver resection, and good survivors, who showed no
evidence of recurrent disease at 60 months after liver resection.
The samples of tumour tissue and adjacent liver parenchyma
were reviewed by an experienced hepatopathologist to judge the
quality of the tissue. Genome-wide mRNA expression profiling







Mean age at time of liver surgery 62.5 ± 9.7 67.7 ± 9.9 0.005
Male sex 23 (48.9%) 50 (64.1%) 0.096
TUMOUR CHARACTERISTICS
Major liver surgery (≥ 3 segments) 34 (72.3%) 18 (23.1%) <0.001
Size largest CRLM (in cm) 4.2 (3.0–7.5) 3.4 (2.0–4.7) 0.001
Rectal primary tumour 15 (31.9%) 34 (43.6%) 0.195
Neoadjuvant chemotherapy 0 0 –
Adjuvant chemotherapy 0 0 –
CLINICAL RISK SCORE
CRS = 3 (high score) 13 (27.7%) 10 (12.8%) 0.038
Interval CRLM < 12 months 22 (46.8%) 33 (42.3%) 0.623
CEA > 200 mg/ul 7 (16.3%) 2 (2.6%) 0.006
More than 1 CRLM 12 (25.5%) 24 (30.8%) 0.531
CRLM larger than 5 cm 17 (36.2%) 12 (15.4%) 0.008
N+ primary tumour 28 (59.6%) 36 (46.2%) 0.146
CRS, clinical risk score; CEA, carcinoembryonic antigen; N+, lymph node positive.
by RNAseq followed by immunohistochemistry was performed
on a cohort of patients treated in the University Medical Centre
Groningen (cohort 1). Corroboration of immunohistochemical
results was performed using tissue samples from patients
with similar inclusion criteria who underwent liver surgery
in another tertiary referral centre for liver surgery in the
Netherlands (cohort 2, Erasmus Medical Centre in Rotterdam).
Baseline clinicopathological characteristics of both cohorts are
summarised in Table 1.
RNA/DNA Isolation
Macrodissected frozen samples of tumour tissue and adjacent
liver parenchyma were included. Both genomic DNA and total
RNA were isolated from 10 µm-tissue sections (RNA/DNA
purification kit, Norgen Biotek Corporation, Thorold, Ontario,
Canada). DNA/RNA isolation was performed according to the
manufacturer’s protocol. Quality check and RNA quantification
of samples was carried out by capillary electrophoresis using the
LabChip GX (Perkin Elmer, Waltham, Massachusetts, USA).
Microsatellite Instability and Mutational
Hotspots
Microsatellite instability (MSI) was tested for all cases by
amplifying 20 ng genomic DNA using primers for five
polymorphic mononucleotide loci (NR21, NR24, BAT25, BAT26,
MONO27). The resulting PCR products were analysed on
the ABI 3730xl DNA Analyzer (Thermo Fisher, Waltham,
Massachusetts, USA). The MSI status was assessed as MSI-
instable when two out of five markers showed instability (18).
For assessment of somatic driver mutations in KRAS (codon 12
and 13) and BRAF (V600E), genomic DNAwas amplified by PCR
and the resulting amplicons were analysed by Sanger sequencing.
Primers are listed in Table S9.
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mRNA Sequencing and Gene Expression
Quantification
Sequence libraries were generated using the Quantseq 3’ mRNA
sample preparation kit (Lexogen, Vienna, Austria) starting from
500 ng total RNA of each sample. Library preparation was
performed according to the manufacturer’s protocol. Quality
check and quantification of libraries was carried out by capillary
electrophoresis using the LabChip GX (Perkin Elmer). Barcoded
libraries were pooled in equimolar ratios aiming at a final
concentration of 2–10 pM. Sequencing was performed on an
Illumina HiSeq2500, applying a 50 bp single-read protocol and
aiming at 5–10 million reads per sample.
The first 12 nucleotides (nt) were trimmed of the 50nt-reads
to remove sequencing artefacts. Hisat version 0.1.5-beta (19)
was used to align reads to human genome reference build 37
(20). SAMtools version 1.2 (21) was used to sort the aligned
reads, and gene-level quantification was then performed by
HTSeq version 0.6.1p1 (22) using “–mode=union,” enabling
strandedness. Because of internal poly-A priming bias, only reads
mapping within 500 bp upstream from the transcript termination
sites—corrected for splicing—were counted, based on Ensembl
version 75 gene annotation (23). Reads in genes with multiple
transcript termination sites were summed up, resulting in a read
count per gene. Genes with an average read count <20 in both
survival groups were excluded from further analysis.
Data and Pathway Analysis mRNA
Sequencing
Data analysis was performed in R (24). To discover possible
bias, a principal component analysis was carried out on all 81
samples after read count normalization by the VSD-function of
the DESeq2 package (25). Samples with <300,000 reads in the
target regions were excluded from further analysis (Table S1).
One sample was removed because of an undesirable patient
characteristic (an additional oncological disease). Differential
expression analysis using DESeq2 was performed separately for
the tumour samples and adjacent liver parenchyma samples
comparing the poor vs. good survivors (25). P-values were
corrected for multiple testing by the Benjamini Hochberg
method (False Discovery Rate, FDR). Heatmap visualizations
were made after read count normalization by the regularized
log transformation of the DESeq2 package, followed by mean
centring per gene (25). Pathway analysis was performed by
DAVID EASE software (26, 27), with p-values corrected for
multiple testing by the Bonferroni method (Family Wise Error
Rate, FWER).
Immunohistochemistry
We included formalin-fixed paraffin-embedded (FFPE) samples
containing both tumour and adjacent liver tissue. Besides
samples from patients treated at the University Medical Centre
Groningen, Groningen, the Netherlands (cohort 1), we also
included samples from patients with similar inclusion criteria
who were treated at the Erasmus Medical Centre, Rotterdam,
the Netherlands (cohort 2). Three µm sections from FFPE
tissue blocks were deparaffinised in xylene, rehydrated in graded
alcohol and hematoxylin and eosin (H&E) stained. H&E stained
slides were examined to confirm the inclusion of the tumour-
liver transition area and to score the histopathological growth
pattern (28). The Ventana automated staining system (Roche,
Basel, Switzerland) was used to stain the tissue sections for
CD45 (RP2/18), CD4 (SP35), CD8 (SP57), CD79A (SP18), and
Kappa/Lambda (double staining, polyclonal). Staining with the
primary antibodies FOXP3 (236A/E7, ABCAM, 1/100 dilution)
and SLAMF7 (HPA055945, Atlas Antibodies, 1/200 dilution) was
done manually. Antigen retrieval in FOXP3-stained slides was
performed in a pressure cooker using a Tris/EDTA buffer (PH
9.0). Antigen retrieval in SLAMF7-stained slides was performed
in the microwave using a citrate buffer (PH 6.0). Primary
antibodies were diluted with 1%BSA/PBS and incubated at room
temperature for 60min. Secondary and tertiary antibodies were
diluted in 1%BSA/PBS and 1% AB serum and incubated at
room temperature for 30min. Appropriate positive and negative
controls were used. Diaminobenzidine (DAB) was used as the
chromogen, followed by a counterstaining by hematoxylin. The
staining of the immunophenotypical markers was graded by
microscopic inspection in a semi-quantitative scoring system for
three different areas: the invasive margin, the tumour stroma
and intra-tumoural region. The invasive margin was defined
as the tumour-liver transition area, the tumour stroma was
defined as the area of stroma surrounding the tumour cells, and
intra-tumoural staining was defined as immunopositive intra-
epithelial lymphocytes in tumour cell areas. The grading of
immunoreactivity was supervised by two experienced researchers
and consensus was achieved in all cases. All markers were scored
in grades 1–3.
Statistical Analysis
Summary statistics were obtained using established methods
and presented as percentages, median (interquartile range, IQR)
or mean (standard deviation, SD). Correlation coefficients of
ranked data were calculated using Spearman’s rho. Variables
associated with survival were first tested by univariable binary
logistic regression analyses comparing poor vs. good survivors.
Variables with a p-value <0.1 in univariable analysis were
entered into the multivariable model. The used multivariable
regressionmodel was a binary logistic regression comparing poor
vs. good survivors, entering all covariates simultaneously and
including a constant in the model. Odds ratio (OR) and 95%
confidence intervals (CI) were estimated, and a p-value <0.05
was considered significant. Statistical analyses were carried out
with IBM SPSS Statistics V22 (IBM, Armonk, New York, USA).
RESULTS
Quality Control
A summary of the mRNA sequencing quality control data
is shown in Table S1. The mean (±SD) number of reads
on target was 1.57 10e6 (±0.75 10e6). The variance in the
dataset was explored by principal component analysis. Principal
component 1 explained 78% of the total variance and showed
a high concordance with tissue type (tumour vs. adjacent liver
parenchyma, Figure S1). The expression of the liver-specific
gene Albumin also resembled the differences in tissue type. Two
adjacent liver samples that clustered with the tumour samples
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had very low levels of Albumin mRNA (0.10 and 0.37% of all
reads in Albumin gene, respectively) compared to the mean
Albumin mRNA level in the adjacent liver samples (6.21% ±
3.10) (Figure S1). Similarly, three tumour samples that clustered
close to adjacent liver samples showed high levels of Albumin
mRNA (10.69, 6.87, and 4.25%) compared to the mean Albumin
expression in the tumour samples (0.65% ± 1.87) (Figure S1).
This suggested a sampling error, and we therefore excluded these
five samples from further analyses. Additionally, five samples
with fewer than 300,000 reads in the target region were excluded.
In total 70 samples were included for further analyses: 39
tumour samples and 31 adjacent liver samples. Of note, for 16
patients both a tumour sample and an adjacent liver sample were
available. The additional 38 samples (70 minus 2∗16) are from
different patients.
Clinicopathological Characteristics
The clinicopathological characteristics of the 39 patients of whom
we included tumour samples are shown in Table S2, stratified
by survival. High preoperative CEA was the only statistically
different variable between both groups, with a high CEA in the
poor survival group (p = 0.049). The clinical risk score, which is
a combined score of five clinicopathological factors (5), was also
significantly higher in the poor survivors (p= 0.031; Table S2).
The clinicopathological characteristics of the 31 patients with
sampled adjacent liver parenchyma are shown in Table S3. There
was no clinicopathological characteristic that was statistically
different between the good and poor survivors.
Tumour-Specific Expression Profiling
After filtering for low read counts, 8,931 genes were included
for further analysis by DESeq2 to identify differentially expressed
genes (DEGs) between the poor vs. good survivors. Of these,
333 DEGs were differentially expressed between the two groups
with a p <0.01, and for 77 of these DEGs the FDR was <0.1
(Table S4). Figure 1 depicts an unsupervised clustering-based
heatmap of the 77 genes with a FDR <0.1, in which a clear
separation of the survival groups is observed. To find out if
specific biological pathways are over-represented in the 333 genes
with p <0.01, we carried out a pathway analysis with DAVID
FIGURE 1 | Heatmap of tumour samples. Unsupervised clustering of the 77 genes with the lowest FDR values in DESeq2 analysis. Samples are shown on the x-axis
and the 77 genes on the y-axis. A quantile colour scale is used with 10 different colours ranging from black (low expression) to yellow (high expression).
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EASE. Two biological entities appeared to be different between
the survival groups (Table S5): the extracellular matrix and the
immune system. The most significant GO-term-related pathway
in each of these two entities was “extracellular matrix” (FWER
= 1.17e-10) and “response to external stimulus” (FWER =
0.039), respectively. In general, a higher expression in both the
extracellular matrix pathways and the immune-system-related
pathways was observed in the good survivors.
Correlation With Estimate
Pathway analysis suggested that the expression of extracellular-
matrix-related genes and immune-related genes is different
between the survival groups (Table S5). We further analysed this
using the ESTIMATE (“Estimation of STromal and Immune cells
in MAlignant Tumours using Expression data”) software (29).
The goal of this software package is to estimate the amount of
stromal cells and immune cells by calculating a stromal score
and an immune score based on 282 genes. The stromal score
was higher in the good survivors (42 ± 603 vs. −469 ± 601;
p = 0.013), as was the immune score (725 ± 660 vs. 317 ± 495;
p = 0.043). Overall, the differences we observed in the mRNA
expression data of the poor vs. good survivors are likely to be
caused by the presence of immune cells and stromal cells in the
tumour samples.
Adjacent Liver Parenchyma Expression
Profiling
Raw read counts of 8,772 genes were used as input for differential
mRNA expression analysis by DESeq2. We compared the poor
vs. good survivors to find DEGs (Table S6), and identified 109
genes with a p <0.01. Of these, only one gene was differentially
expressed between the survival groups with a FDR <0.1:
MTRNR2L1 was more highly expressed in the good survivors
(Table S6). The relatively high FDRs in this analysis indicate that
the results from the adjacent liver parenchyma analysis are not
as reliable as the results from the tumour samples. A pathway
analysis including the 109 DEGs was performed with DAVID
EASE. The transfer RNA pathway was significantly enriched
and had, in general, a higher expression in the poor survivors
(Table S7). Unsupervised clustering did not show uniform DEGs
across the adjacent liver samples, as can be seen in the heatmap
(Figure S2). The separation of the survival groups is not as clear
as that seen in the tumour samples (Figure 1). Therefore, in
the validation, we focused on the mRNA expression data of the
tumour samples.
Immunohistochemistry
Tissue slides of two cohorts were analysed, in which cohort 1
consisted of 47 patients (Groningen) and cohort 2 of 78 patients
(Rotterdam). The samples in cohort 1 are mostly from the
same patients included in the mRNA expression analysis. Table 1
shows that patients in cohort 1 had larger tumours, higher CEA
levels, more frequent major liver surgery and a higher clinical risk
score; Of note, all these variables are interrelated. Additionally,
patients in cohort 2 had an older age.
To study the expression of stroma-related genes, a small pilot
experiment was performed in which immunohistochemistry on
11 tumour tissue slides was performed using four stroma-
related markers (FBLN1, MMP2, PRRX1, ABLIM1) that were
differentially expressed in the mRNA expression analysis. The
results did not validate the sequencing results (data not shown).
We then hypothesized that the stroma-related differences might
resemble the histopathological growth pattern (28). The two
most prevalent growth patterns are a desmoplastic growth
pattern, which is characterized by a rim of stromal cells
between the tumour cells and the adjacent liver cells, and a
replacement growth pattern, which lacks a desmoplastic rim.
A 100% desmoplastic growth pattern was associated with good
survival in both cohort 1 and 2 (p = 0.089 and p = 0.008,
respectively; Table 2).
The mRNA expression data prompted us to stain tumour
sections to validate immune-related expression, by which
we chose seven immunophenotypical markers [CD45, CD4,
CD8, FOXP3, CD79A, Kappa/Lambda (K/L) and SLAMF7]
to study both T cell and B cell expression. Besides T cell
markers we also chose to stain B cell markers as multiple
immunoglobulin genes were differentially expressed between the
survival groups (Table S5). CD45+ andCD4+ cells generally had
a higher abundancy compared to the other markers. Figure 2
shows detailed pictures of the staining. Table 2 shows the
clinicopathological characteristics and the scoring of the seven
immunophenotypical markers in the poor vs. good survivors of
both cohorts separately and combined. The clinical risk score
was a good predictor of survival in cohort 1 (p =0.006; Table 2),
while in cohort 2 and the combined cohort the CRS was a less
good predictor of survival [p= 0.931 and p= 0.055, respectively
(Table 2)]. A high CD79A expression in the tumour stroma
tended to be associated with good survival in both cohort 1
and 2 (p = 0.069 and p = 0.054, respectively). Similarly, K/L
expression in the tumour stroma also tended to be associated
with good survival in cohorts 1 and 2 (p = 0.081 and p = 0.070,
respectively). A 100% desmoplastic growth pattern tended to
be associated with good survival in cohort 1 (p = 0.089) and
was significantly associated with good survival in cohort 2 (p =
0.008; Table 2).
Multivariable Analysis
A multivariable analysis was performed to test whether
immunohistochemical markers have significant impact
in predicting patient survival. The three most significant
biomarkers were analysed in multivariable analysis (Table 3).
Immunohistochemical markers that might be associated with
good survival in cohorts 1 and cohort 2 were (respectively): high
K/L+ infiltration in tumour stroma [p= 0.124; OR 2.682 (95%CI
0.762–15.248] and p = 0.067; OR 2.589 [95%CI 0.934–7.171)],
high CD79A+ infiltration in tumour stroma [p = 0.110; OR
2.740 (95%CI 0.795–9.443)] and p = 0.095; OR 2.443 [95%CI
0.856–6.978)], and a 100% desmoplastic growth pattern [p =
0.157; OR 2.709 (95% CI 0.682–10.768) and p = 0.040; OR 5.858
(95%CI 1.083–31.693)]. These three biomarkers are significantly
associated with patient survival (all p < 0.05) if we combine
data from cohort 1 and 2 (Table 3). If we correct only for the
clinicopathological factor CRS (high vs. low) in the total cohort,
high K/L+ infiltration in tumour stroma [p = 0.026; OR 2.359
Frontiers in Oncology | www.frontiersin.org 5 March 2020 | Volume 10 | Article 249
Hof et al. B Lymphocytes and Liver Metastases
TABLE 2 | Clinicopathological and biological markers vs. survival in cohorts 1, 2 and combined.




















Mean follow-up in months 16.6 ± 5.5 112.3 ± 36.1 <0.001 17.0 ± 6.7 122.7 ± 36.0 < 0.001 16.9 ± 6.3 118.6 ± 36.1 <0.001
PATIENT CHARACTERISTICS
Mean age at liver surgery 62.6 ± 10.9 62.4 ± 8.8 0.939 71.0 ± 8.7 64.6 ± 10.1 0.004 68.0 ± 10.3 63.7 ± 9.6 0.017
Male sex 13 (61.9%) 10 (38.5%) 0.110 28 (73.3%) 22 (55.0%) 0.086 41 (69.5%) 32 (48.5%) 0.017
TUMOUR CHARACTERISTICS
Major liver surgery (≥ 3 segments) 18 (85.7%) 16 (61.5%) 0.065 6 (15.8%) 12 (30%) 0.137 24 (40.7%) 28 (42.4%) 0.843
Size largest CRLM (in cm) 4.5 (3.8–12.5) 4.2 (3.0–5.2) 0.134 3.9 (2.5–4.8) 3.0 (1.8–4.5) 0.072 4.0 (2.6–5.5) 3.5 (2.0–5.0) 0.050
Rectal primary tumour 9 (42.9%) 6 (23.1%) 0.148 18 (47.4%) 16 (40%) 0.512 27 (45.8%) 22 (33.3%) 0.155
Neoadjuvant chemotherapy 0 0 – 0 0 – 0 0 –
Adjuvant chemotherapy 0 0 – 0 0 – 0 0 –
CLINICAL RISK SCORE
CRS = 3 (high score) 10 (47.6%) 3 (11.5%) 0.006 5 (13.2%) 5 (12.5%) 0.931 15 (25.4%) 8 (12.1%) 0.055
Interval CRLM < 12 months 10 (47.6%) 12 (46.2%) 0.920 17 (44.7%) 16 (40%) 0.672 27 (45.8%) 28 (42.4%) 0.707
CEA > 200 mg/ul 5 (27.8%) 2 (8.0%) 0.083 1 (2.6%) 1 (2.5%) 0.971 6 (10.7%) 3 (4.6%) 0.202
More than 1 CRLM 7 (33.3%) 5 (19.2%) 0.270 15 (39.5%) 9 (22.5%) 0.104 22 (37.3%) 14 (21.2%) 0.048
CRLM larger than 5 cm 10 (47.6%) 7 (26.9%) 0.142 6 (15.8%) 6 (15%) 0.923 16 (27.1%) 13 (29.7%) 0.326
N+ primary tumour 14 (66.7%) 14 (53.8%) 0.373 19 (50%) 17 (42.5%) 0.507 33 (55.9%) 31 (47.0%) 0.317
MOLECULAR CHARACTERISTICS
Microsatellite instability (MSI-high) 2 (9.5%) 1 (3.8%) 0.429 – – – – – –
KRAS mutation (codon 12 and 13) 9 (42.9%) 9 (34.6%) 0.563 – – – – – –
BRAF V600E mutation 0 0 – – – – – – –
GROWTH PATTERN
100% desmoplastic 4 (19.0%) 11 (42.3%) 0.089 2 (5.3%) 11 (27.5%) 0.008 6 (10.2%) 22 (33.3%) 0.002
GENERAL LYMPHOCYTES
High CD45 tumour stroma 3 (14.3%) 5 (19.2%) 0.654 5/37 (13.5%) 9 (22.5%) 0.307 8/58 (13.8%) 14 (21.2%) 0.281
High CD45 invasive margin 9 (42.9%) 10 (38.5%) 0.760 9 (23.7%) 9 (22.5%) 0.901 18 (30.5%) 19 (28.8%) 0.833
T-CELLS
High CD4 tumour stroma 4 (19.0%) 8 (30.8%) 0.360 3/36 (8.3%) 6 (15%) 0.369 7/57 (12.3%) 14 (21.2%) 0.189
High CD4 invasive margin 7 (33.3%) 12 (46.2%) 0.373 4 (10.5%) 8 (20%) 0.246 11 (18.6%) 20 (30.3%) 0.132
High CD8 tumour stroma 12 (57.1%) 13 (50%) 0.626 17/37 (45.9%) 20 (50%) 0.722 39/58 (50%) 33 (50%) 1.000
High CD8 invasive margin 14 (66.7%) 20 (76.9%) 0.435 19 (50%) 28 (70%) 0.071 33 (55.9%) 48 (72.7%) 0.050
High CD8 intratumoural 10 (47.6%) 10 (38.5 %) 0.528 14 (36.8%) 11 (27.5%) 0.377 24 (40.7%) 21 (31.8%) 0.303
High FOXP3 tumour stroma 17 (81.0%) 24 (92.3%) 0.246 13/36 (36.1%) 25 (62.5%) 0.022 30/57 (52.6%) 49 (74.2%) 0.013
High FOXP3 invasive margin 17 (81.0%) 22 (84.6%) 0.740 24/37 (64.9%) 26 (65%) 0.990 41/58 (70.7%) 48 (72.7%) 0.801
B-CELLS
High CD79A tumour stroma 9 (42.9%) 18 (69.2%) 0.069 20/37 (54.1%) 30 (75%) 0.054 29/58 (50%) 48 (72.7%) 0.009
High CD79A invasive margin 14 (66.7%) 16 (61.5%) 0.716 23 (60.5%) 33 (82.5%) 0.031 37 (62.7%) 49 (74.2%) 0.165
High K/L tumour stroma 6 (28.6%) 14 (53.8%) 0.081 11/37 (29.7%) 20 (50%) 0.070 17 (29.3%) 34 (51.5%) 0.012
High K/L invasive margin 7 (33.3%) 14 (53.8%) 0.160 16 (41.0%) 18 (45%) 0.721 23 (39.0%) 32 (48.5%) 0.285
High SLAMF7 tumour stroma 7 (33.3%) 9 (34.6%) 0.927 14/37 (37.8%) 18 (45%) 0.524 21/58 (36.2%) 27 (40.9%) 0.592
High SLAMF7 invasive margin 11 (52.4%) 15 (57.7%) 0.716 17 (44.7%) 19 (47.5%) 0.807 28 (47.5%) 34 (51.5%) 0.651
A high CD4 and CD45 infiltration is defined as a grading of 3. In the other markers, a high infiltration was defined as a grading of ≥ 2. CRS = clinical risk score, CEA = carcinoembryonic
antigen, N+ = lymph node positive.
(95% CI 1.109–5.019) as high CD79A+ infiltration in tumour
stroma (p = 0.031; OR 2.338 (95% CI 0.1.081–5.056)] as a 100%
desmoplastic growth pattern [p = 0.007; OR 3.952 (95% CI
1.454–10.742)] were all significantly associated with favourable
survival whereas the CRS was not (p = 0.168; p = 0.103; p =
0.163, respectively).
Statistical correction for clinicopathological factors did
not uniformly improve the prognostic value of biomarkers
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TABLE 3 | Multivariable analysis to predict survival.
Univariable Multivariable
Factor P OR (95% CI) P OR (95% CI)
















































Three biomarkers were analysed in multivariable analysis. Each biomarker is adjusted for the most significant prognostic clinical factor(s) within the respective cohort according to the
“one variable per 10 events” rule (30). In cohort 1, the variables were corrected for “major liver surgery (≥ 3 segments)”. In cohort 2, correction was performed using the variables: age,
sex and tumour size. In the combined cohort, correction was performed using the variables: age, sex, solitary tumour, tumour size, and cohort. An odds ratio >1 corresponds with good
survival. CI, confidence interval; K/L, Kappa Lamda.
FIGURE 2 | Detailed pictures of immunohistochemistry. (A) x10 magnification image of high Kappa/Lambda + staining in the tumour stroma. Kappa light chains are
stained brown, Lambda light chains are stained pink. (B) x4 magnification image of high CD79A+ staining (brown) in the invasive margin. (C) x10 magnification image
of a replacement growth pattern by H&E staining. (D) x10 magnification image of a desmoplastic growth pattern by Masson’s trichrome staining. Tumour and liver
cells are stained purple, connective tissue (desmoplastic rim) is stained blue. Tu, tumour; Li, liver; St, tumour stroma.
in multivariable analysis (30). This is partly explained by
an association between the clinical marker tumour size and
protein expression (Table S8). Of note, in patients with more
than one metastasis (n = 36; 29% of all cases), the tumour
with the largest diameter was used for immunohistochemical
staining in 28 out of 36 patients. A desmoplastic growth
pattern was associated with smaller tumour size [2.8 cm
(1.5–4.9) vs. non-desmoplastic growth pattern 3.8 cm
(2.6–5.1); p = 0.029]. In addition, high stromal CD79A+
infiltration was also associated with smaller tumour size
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[3.4 cm (2.0–4.5) vs. low CD79A+ infiltration 4.1 cm
(3.0–7.0); p = 0.011]. Especially B cell-related markers
scored in the invasive margin were associated with size of
the tumour (Table S8).
DISCUSSION
In this study we used mRNA sequencing to identify prognostic
molecular markers in patients after liver surgery for colorectal
liver metastases. We selected two patient groups: poor survivors
(death due to recurrence within 30 months) and good survivors
(disease-free survival > 60 months after liver surgery). We show
that patients with good survival had a higher expression of
immune-related and stroma-related genes. Additional analysis
by ESTIMATE software indicated higher immune cell and
stromal cell infiltration in the tumour samples of good survivors
(29). Immunohistochemistry showed in two cohorts that high
immune infiltration of CD79A+ B cells and K/L+ plasma cells
in tumour stroma tended to be associated with good survival.
Comparable results from these biomarkers were observed in
multivariable analysis correcting for clinicopathological factors.
In addition, the desmoplastic growth pattern, in which a
stroma-rich pseudo-capsule around the tumour is present, might
also be associated with good patient survival. The prognostic
value of a desmoplastic growth pattern has been reported
previously (31–36). In contrast, the associations between good
patient survival and high stromal infiltration of CD79A+
cells and K/L+ cells are, to the best of our knowledge,
novel findings.
The top differentially expressed genes in the tumour samples
in this study did not overlap with those of the four previously
published expression signatures (9–12). However, no individual
gene was shared between these earlier studies either (9–12).
This may partly be explained by the different experimental
methods used by the studies. We used mRNA sequencing,
while the earlier studies used different expression microarrays
(9–12, 37). The inclusion criteria for patients were also very
different between studies. Our study and that of van der
Stok et al. (11) did not administer neoadjuvant or adjuvant
chemotherapy to included patients, while the three other studies
did (9, 10, 12). Neoadjuvant chemotherapy influences tumour
biology andmight thereby alter gene expression levels (38). Three
of the studies aimed at identifying genes that are associated
with recurrence rather than with overall survival (10–12), and
the cut-off values to stratify rapid recurrence vs. late or no
recurrence differed per study: Snoeren et al. (10) included
patients with DFS ≤1 year vs. DFS >1 year, Snoeren et al.
(13) included patients with DFS <6 months vs. DFS > 2
years, and van der Stok et al. included patients with DFS ≤1
vs. DFS >3 years. In our opinion we used the most straight-
forward inclusion by selecting chemotherapy-naïve patients, the
strongest endpoint (disease-related overall survival; death of
recurrent disease within 30 months vs. alive and free of disease
5 years after liver surgery) and the most accurate gene expression
technology. These inter-study differences might explain the lack
of shared genes.
We also studied adjacent liver parenchyma and found a
significantly higher expression of MTRNR2L1 in the good
survivors. This gene is an isoform ofMT-RNR (humanin), which
is reported to have neuroprotective and anti-apoptotic functions
and is mainly studied in age-related illness like Alzheimer’s
disease (39, 40).
In our study, the B-cell-related immunohistochemical
markers CD79A and K/L suggest an association with patient
survival. There are no previous studies that analysed CD79A
and K/L in CRLM, but the prognostic value of B-cell marker
CD20 was analysed by four other studies (41–44). Two studies
reported an association of high CD20+ B cells in the invasive
margin with a favourable overall survival (41, 44). In addition,
one of these studies also showed an association between high
CD20+ B cells in the tumour stroma and a favourable survival
(41). Two other studies observed no associations with patient
survival (42, 43). The results in literature are diverse when
focussing on the role of the immune system on prognosis after
surgery for CRLM (45). Although the role of tumour-infiltrating
B cells and immunoglobulins is not as well-described as the
role of tumour-infiltrating T cells, an association between B cell
infiltration and favourable patient survival has been reported
for other solid tumours (46–48). Anti-tumour immunity can be
achieved through immunoglobulin production by plasma cells
and, moreover, through increased cytotoxic T cell activation
via antigen presenting B cells (46–48). In contrast, others have
questioned the actual effect of the B cell response (47, 48).
It is also proposed that the B cell infiltration is the result of
IFNγ production and serves as a surrogate marker of the
T-cell-mediated anti-tumour response (47).
CONCLUSIONS
In conclusion, our study of the liver metastasis of patients
with colorectal cancer showed that high stromal infiltration of
CD79A+ B cells and high stromal infiltration of K/L+ plasma
cells might be favourable prognostic biomarkers after surgery
for CRLM. Future evaluation on external cohorts is needed to
prove whether these biomarkers truly are associated with patient
survival and of practical clinical value.
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